Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18295013 | 0.88 | SOS1 (0.40) | OPRL1KIF11SOS1SLC6A2SLC6A4 | |
| SCHEMBL22502738 | 0.87 | OPRL1 (0.45) | RPS6KA3PDE2AOPRL1KIF11GAA | |
| SCHEMBL765783 | 0.85 | BACE1 (0.41) | OPRL1KIF11SOS1 | |
| SCHEMBL14297935 | 0.85 | BACE1 (0.44) | OPRL1KIF11SOS1 | |
| SCHEMBL14314452 | 0.83 | NUDT1 (0.46) | OPRL1KIF11SOS1 | |
| SCHEMBL21644870 | 0.78 | ESR1 (0.39) | OPRL1SOS1 | |
| SCHEMBL20103372 | 0.78 | ESR1 (0.39) | OPRL1SOS1 | |
| SCHEMBL16220939 | 0.78 | PLK4 (0.41) | OPRL1GAA | |
| SCHEMBL21533899 | 0.77 | SYK (0.45) | — | |
| SCHEMBL8264162 | 0.77 | OPRL1 (0.38) | RPS6KA3PDE2AOPRL1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | RPS6KA3 253/4885PDE2A 2297/4885OPRL1 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.